Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Construction of the plant will commence in 2025 with first production expected to be in 2027
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Subscribe To Our Newsletter & Stay Updated
